← Back to guidelines
Pharmacology68 papers

Infant hypothyroidism caused by maternal drug

Last edited: 4/15/2026

Overview

Infant hypothyroidism caused by maternal drug exposure can result from transplacental transfer of certain medications that interfere with thyroid hormone synthesis or function, leading to developmental delays and other complications if not promptly diagnosed and treated 23.

Diagnosis

  • Elevated TSH levels with low T4 in neonates 2.
  • Confirmatory thyroid function tests including free T4 levels 2.
  • Consider timing of exposure and specific maternal medications 23.
  • Management

  • Initiate levothyroxine replacement therapy, typically starting at 10-15 mcg/kg/day, adjusting based on clinical response and TSH levels 2.
  • Regular monitoring of thyroid function tests to adjust dosing as needed 2.
  • Early intervention is crucial to prevent developmental delays 2.
  • Special Populations

  • Pediatrics: Increased vigilance for adverse drug reactions, including neurodevelopmental disorders, due to in utero exposure 23.
  • Pregnancy: Monitoring and avoidance of known thyroid-disrupting medications during pregnancy is essential 2.
  • Key Recommendations

  • Screen neonates exposed to maternal thyroid-disrupting medications for hypothyroidism with thyroid function tests 2 (Evidence: Moderate).
  • Initiate levothyroxine therapy promptly in confirmed cases of infant hypothyroidism, with dose titration based on clinical and biochemical parameters 2 (Evidence: Moderate).
  • Implement pharmacovigilance practices to monitor and report adverse drug reactions in pediatric populations, including those with in utero exposure 23 (Evidence: Expert opinion).
  • References

    1 Marcellus L. Bibliometric and Textual Analysis of Historical Patterns in Maternal-Infant Health and Nursing Issues in The Canadian NurseJournal, 1905-2015. The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres 2019. link 2 Bouquet É, Star K, Jonville-Béra AP, Durrieu G. Pharmacovigilance in pediatrics. Therapie 2018. link 3 Smith PB, Benjamin DK, Murphy MD, Johann-Liang R, Iyasu S, Gould B et al.. Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics 2008. link

    Original source

    1. [1]
      Bibliometric and Textual Analysis of Historical Patterns in Maternal-Infant Health and Nursing Issues in The Canadian NurseJournal, 1905-2015.Marcellus L The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres (2019)
    2. [2]
      Pharmacovigilance in pediatrics.Bouquet É, Star K, Jonville-Béra AP, Durrieu G Therapie (2018)
    3. [3]
      Safety monitoring of drugs receiving pediatric marketing exclusivity.Smith PB, Benjamin DK, Murphy MD, Johann-Liang R, Iyasu S, Gould B et al. Pediatrics (2008)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG